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Abstract
7KHXVHRIJHQHWKHUDS\DVDPHGLFDOWUHDWPHQWRSWLRQZDVÀUVWLQWURGXFHGWRWKHZRUOGLQ ZKHQDIRXU\HDUROGJLUO
EHFDPH LWV ÀUVW SDWLHQW 6LQFH WKHQ JHQH WKHUDS\ KDV PHW JUHDWVXFFHVV EXW DOVR VHYHUH GUDZEDFN  ,QFLGHQFHV ZLWK VHYHUHO\
negative outcomes on patients gave gene therapy a bad name and many began skeptical towards its use, but the constant work
and progress on the safety and effectiveness of gene therapy is making it a more viable route of treatment. This paper focuses
RQJHQHWKHUDS\DVDIRUPRIFDQFHUWUHDWPHQW9LUDOLQVHUWLRQRIWKHPRGLÀHGJHQHWLFPDWHULDOLVWKHPRVWHIIHFWLYHPHWKRGRI
insertion, targeting a large number of cells, although physical insertion may be safer and more economical. The mechanism by
which many gene therapies work is suicide genes, genes that cause the cell they enter to lyse. The paper goes on to discuss the
+ORFXVRQWKHJHQRPHZKLFKSOD\VDVLJQLÀFDQWUROHLQFDQFHUGHYHORSPHQWDQGFRQYHUVHO\WUHDWPHQW%&LVDSODVPLG
WKDWLVV\QWKHWLFDOO\SURGXFHGWRWUHDWFDQFHUEDVHGRQWDUJHWLQJWKH+ORFXV5HVHDUFKDQGWHVWPRGHOVRIWKH%&VKRZ
promising results for many cancer patients.
Introduction
Cancer is the second leading cause of death worldwide, taking
the lives of over 8.2 million people every year.The standard cancer treatments, such as chemotherapy and radiation therapy, are
often inadequate and debilitating, destroying healthy fast-growing cells in the process of treatment. Over the past decade,
gene therapy has become a more prevalent option for treating
cancers. Gene therapy avoids targeting healthy cells, selecting
only cancerous cells for treatment. There are three approaches
to gene therapy immunotherapy: stimulating a patient’s immune
system to recognize and attack cancer cells, oncolytic virotherapy, which generally uses viruses to infect and kill cancer cells,
and gene transfer, which is the insertion of genetic material into
the cancerous cells. This paper aims to consider the viability of
gene transfer therapy. Gene transfer therapy is an exciting new
technology that is shifting the paradigm of cancer treatment.
It involves inserting a foreign gene directly into the cancerous
cells or surrounding tissue’s genome (Cross, Brumester 2006).
With all the strides and progress made in gene transfer there
DUHVWLOOSUREOHPVWKDWQHHGWREHUHFWLÀHG,QHDUO\VDIHW\WHVW
cases, gene transfer scared many by causing the death of a patient (Raper, et. al. 2003). Also, in some cases, gene transfer
methods have promoted leukemia in their attempt to cure the
patient of his disease (Thomas, et. al. 2003). Additionally, there
is still plenty of research yet to be done in this area due to its
relative newness. This paper will assess how much of an option
gene therapy is for cancer patients, taking into account its nuPHURXVEHQHÀWVDQGVRPHWLPHVVHYHUHGUDZEDFNV

Methods
Research literature for this paper was obtained through the
Touro College Online library. Searches done on the Touro
College Online library led the student to Proquest and Pubmed,
where majority of the articles were obtained. Articles found on
other scholarly sites were also used. The articles discussed experimental studies done and the thorough analysis of these articles allowed for the assessment of gene therapy’s practicability.
Review articles also assisted in composing the formal analysis.

Discussion
The standard treatment method for cancer today is chemotherapy. Chemotherapy can cause an array of both short term and

long term side effects. Short term side effects are side effects
that are present during the time of treatment and are often
reversible, while long term side effects cause more severe and
permanent damage. Short term side effects include hair loss,
nausea, and vomiting, which can sometimes hinder patient compliance. Long term side effects such as arthritis, appendicitis,
and thyroid damage have less of a probability of occurring, but
do occur in some patients (Ramirez, et. al. 2009). The above
mentioned are general side effects, but each patients’ individual
circumstance can pose other possible risks. If patients could be
assured that chemotherapy would remove the cancer in totality,
undergoing chemotherapy would be more tolerable, yet in many
cases the chemotherapy fails to rid the body from the cancer
and therefore, is often not a preferable option.
In this paper, gene therapy will be analyzed to assess whether
it is a better option of treatment for cancer patients or whether
it is yet another treatment method that provides partial results
DQGFDXVHVVHYHUHVLGHHIIHFWV+RZHIÀFLHQWJHQHWKHUDS\LVLQ
treating cancer, what side effects it includes and what the severity of the side effects are all questions that need to be addressed.

Insertion Approaches
There are two approaches to gene insertion; it can be done
by means of either a viral or a non-viral vector (Amer, 2014).
A viral insertion uses a virus as a vector to harbor the drug. A
non-viral vector, which generally uses naked DNA or toxic material for the cell as a vector, can be inserted either chemically
or physically. Physical insertion can be done by a gene gun or
ultra sound. Another physical approach is that of electroporation, which uses high voltages of electricity to disrupt the cell’s
membrane, allowing the drug to enter the cell (Baranyi, et. al.
2013).

Viral Insertion
Viruses have long been a choice for a vector because of some
important properties they contain. Viruses are small pathogenic
particles that contain either DNA or RNA encoded in a protein
coat. Some viruses also contain a lipid bilayer surrounding the
protein coat. The mechanism in which a virus infects a cell is
by implanting itself on the host cell’s membrane and inserting
its viral DNA into the host cell. The host cell then transcribes
and translates the viral DNA, which codes for the creation and
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assembly of more viral particles. These new viruses cause the
cell to burst and proceed to infect more cells. The mechanism
by which the virus operates is useful, for genetic material that
will lead to cancer cell death or degeneration can be placed
in a virus vector, which is essentially the outer protein coat of
the virus deprived of its viral genome, and then infect the target tissue area. Before using it as a vector, the virus has to be
rendered non replicative so it no longer behaves as a pathogen.
Viral vectors are advantageous since they can be produced in
high concentrations and have minimal side effects (Amer, 2003).
The most popularly used viral vector is the adenovirus. The
adenovirus is favored since it can be made in high titers and can
infect both dividing and non-dividing cells. When using a viral
vector such as the adenovirus, steps must be taken to ensure
that the virus will not reproduce in the host’s body like it naturally would. Prevention of the adenovirus replication can be
achieved by removing early regions of the adenovirus vector’s
genome (Pulkkanen, et. al. 2005).

Comparing Adenovirus to Retrovirus
$FRPSDULVRQRIWKHHIÀFLHQF\RIWKHDGHQRYLUXVDQGWKHUHWURvirus as vectors for gene transfer was done. Ten patients with
malignant glioma, a spreading brain tumor, were treated with a
beta galactosidase gene via retrovirus and adenovirus vectors.
This was done by inserting a catheter into the tumor and injecting the patient with retroviruses and adenoviruses for three
consecutive days. This was followed by resection of the tumor
one to two days later. X-gal staining was then used to highlight
WKHEHWDJDODFWRVLGDVHJHQHDQGWRHYDOXDWHLWVHIÀFDF\LQJHQH
transfer. Findings showed that beta galactosidase was well tolerated with both vectors. In all but two patients, no systemic
or tissue complications were apparent. The gene transfer was
VXFFHVVIXOZLWKDQHIÀFDF\EHWZHHQIRUWKHUHWURYLUXV
DQG DQ HIÀFDF\  IRU WKH DGHQRYLUXV 7KH DGHQRYLUXV
ZDVWKXVPRUHHIÀFLHQWWKHQWKHUHWURYLUXVDVDJHQHWUDQVIHU
vector (Puumalainen, et. al. 1998).

Malignant Glioma Adenoviral Gene Therapy
$OWKRXJK DGHQRYLUDO YHFWRUV KDYH VRPH RI WKH KLJKHVW HIÀFDFLHV
of gene transfer amongst other viral vectors, they still fall short of
SURGXFLQJVLJQLÀFDQWHIIHFWVRQWKHWUHDWPHQWRIWXPRUV$VWXG\RI
the treatments of malignant glioma was conducted with the aim of
evaluating the safety of the adenoviral vector as well as determining
the maximum possible dose that would be tolerated. Fourteen patients with relapsed malignant glioma were treated with adenoviral
vector containing the Herpes simplex virus thymidine kinase (HSVtk) and its promoter (IG.Ad.MLPI.TK), and were then treated with
ganciclovir, an antiviral drug. Prior to this the retrovirus had been
used as a vector for HSV-tk gene therapy treatment. However, the
adenovirus was used in this study because of its advantages of high
WLWHUSURGXFWLRQDQGHIÀFDF\RIJHQHWUDQVIHU
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The patients underwent as much debulking of the tumor as
ZDVFRQVLGHUHGVDIH7KHZRXQGEHGZDVWKHQLQÀOWUDWHGZLWK
around 50 evenly spaced injections of the HSV-tk gene. The
patients were treated with different dose levels and then monitored for any adverse events. The patients reported either
adverse events or serious adverse events. From surgery until
completion of the ganciclovir treatment, 27 adverse events and
5 serious adverse events were reported. However none of the
adverse events or serious adverse events were from the adenoviral vector.
After surgery, the patients were kept in strict isolation in the
ICU, and viral cultures were taken until there were two consecutive days of negative culture results. None the cultures taken
were found to be positive, indicating that the viral vector did
not shed during its administration and did not pose a hazard to
the environment.
The adenovirus was thus considered to be a safe vector internally and externally. However, in regard to the results of the
patients’ tumor responses, the adenovirus does not appear as
promising. Unfortunately, none of the tumors responded to the
successful gene transfer. Overall the patients did not fare well.
The median survival time was four months, with four patients
surviving for over a year. The median survival time attained in this
study with the injection of the adenoviral vector was no better
than the survival time in respective studies of malignant glioma
with no gene therapy treatment. According to the study, even the
survival of patients with the favorable prognosis was most likely
due to the nature of the tumor and not the gene transfer.
It is clear that the adenoviral vector used in this study is a
VDIH PHWKRG RI FKRLFH EXW QRW VLJQLÀFDQWO\ HIIHFWLYH LQ GLPLQLVKLQJWKHWXPRUJURZWK,WLVQRWGHÀQLWLYHIURPWKLVVWXG\LI
the adenoviral gene transfer had even any effect on the tumor.
(Smitt, et. al. 2003).
In contrast to viral vectors, non-viral vectors are generally
more economical and easier to produce in large quantities.They
also have limited immunogenicity which allows for re-dosing.
There is no concern of a gene recombination causing the virus
to become competent and pose a danger to the body (Amer,
et. al. 2014).

Physical Insertion
Physical insertion involves injecting naked DNA or liposomes
directly into the target cell through a breach in the membrane
made by rapid needle or jet injections, particle impact, electric
pulse, laser radiation, or ultrasound. A novel method of physical
LQVHUWLRQLVWKH-HWLQMHFWLRQZKLFKZDVÀUVWLQWURGXFHGLQ
as an alternate to needle injections. Jet injection uses a presVXUL]HGJDVOLNHFDUERQGLR[LGHWRGULYHDQXOWUDÀQHKLJKVSHHG
stream of DNA into the target tissue in the form of plasmids.
Comparisons done between jet and needle injections demonVWUDWHG WKDW JHQH H[SUHVVLRQ ZDV ÀIW\ WLPHV JUHDWHU ZKHQ
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done by jet injection than it was done by the standard needle
injection.
A phase 1 study was conducted to determine the safety and
feasibility of jet injection on patients with skin metastases from
PHODQRPDDQGEUHDVWFDQFHU6HYHQWHHQSDWLHQWVUHFHLYHGÀYHMHW
injections of B-galactosidase, a LacZ- expressing DNA plasmid,
into a single cutaneous lesion. To monitor the clearance of the
plasmid in the blood stream, real time quantitative PCR of blood
samples was done throughout the study. After two to six days,
the lesions were resected and a series of tests were performed
WRGHWHUPLQHWKHHIÀFLHQF\RIWKHSODVPLGXSWDNHDVZHOODVWKH
transcription of DNA to mRNA and translation to a protein.
All the patients responded well to the jet injections. Four
weeks after jet injection, all the patients were alive and none
showed any adverse effects from the jet injection. Within
forty-eight hours any small bleeding and jet penetration at
the injection site disappeared. Additionally, the LacZ plasmids
were successfully taken up by all the tumors, with variation in
amounts detected in each tumor (Wolfgang, et. al. 2008).
Because this was a phase 1 study, research was taken to determine the safety of the jet injection and did not cover the
HIÀFDF\RIMHWLQMHFWLRQLQUHGXFLQJFDQFHURXVJURZWK7KH/DF=
gene did not have any association to reduction of cancerous
growth, but rather served as a marker to determine if jet injection was a viable method of gene transfer. Research on humans
using jet-injection-based gene transfer as antitumor therapy is
limited and quite recent.There have been studies done on mice,
though, with encouraging results.
A study was conducted on mice containing human colon carcinoma to test the effectiveness of gene transfer jet injection in its ability
to inhibit tumor growth. The mice were injected four times with
a suicide gene, Escherichia coli cytosine deaminase, and then after
IRUW\HLJKWKRXUVWUHDWHGZLWKÁXURF\WRFLQH DQDQWLIXQJDOGUXJ
7XPRUYROXPHVZHUHPRQLWRUHGDQGVWDUWLQJRQGD\ÀYHWKHUHZDV
DVLJQLÀFDQWGHFUHDVHLQWKHVL]HRIWKHWXPRUVWUHDWHGZLWKWKHMHW
injected suicide gene in comparison to the control groups’ tumors.
Additionally, protein and mRNA levels revealed that the suicide
JHQHZDVVXIÀFLHQWO\H[SUHVVHG :DOWKHUHWDO 
Although this study was not conducted on humans, it still has
VLJQLÀFDQWÀQGLQJVFKLHÁ\WKDWQRQYLUDOMHWLQMHFWLRQRIVXLFLGH
genes is an alternate method to injection via viral vectors, with
comparable therapeutic response. Though there are studies, as
mentioned above, of successful adenoviral vector gene transfers,
the adenoviral vector does have limitations that the jet injection
does not. When using the adenovirus as a vector, there is always
the concern that it may have a pathogenic effect on the patient,
or that the patient’s immune system will respond to the viral
proteins and inhibit the vector in completing its task. Jet injection looks promising for cancer treatment, but it is only useful
for subcutaneous cancerous growths, like that of melanoma and
breast cancer, since it cannot penetrate very deep.

Suicide Genes
Once the genetic material is successfully transferred into the
host cancer cells and incorporated into the nuclear genetic
DNA, there are a few methods by which it represses tumor
growth. A key method being the injection of suicide genes,
which are genes that cause apoptosis, or cellular death, when
expressed. These genes are usually transcribed by various promoters found within the host cell. The H19 RNA gene is an
example of one such promoter. The H19 gene locus was the
ÀUVWLPSULQWHGQRQFRGLQJ51$LGHQWLÀHG5HFHQWO\H[WHQVLYH
study has been done on the role of the H19 gene and tumorigenesis. It is found that there is an abnormal expression
of the H19 RNA gene in many cancerous cells, causing cancer
cell proliferation, genetic instability, vascular angiogenesis, and
tumor metastases. In a number of studies, blocking the H19
gene led to tumor regression and necrosis (Amer, et. al. 2014).

H19 Locus and tumorigenesis
The H19 RNA gene is greatly expressed in fetal organs but
is rapidly turned off at birth. In tumor cells, the H19 gene
becomes highly expressed or shows an abnormal expression
pattern when compared to normal non-cancer cells. In cancer
cells, the H19 gene expression can be activated by a combination of various transcriptional modulators and regulators that
have malfunctioned. The interplay of the H19 gene locus and
the modulators in tumorigenesis is highly complex, involving
many regulatory factors that rely on many other regulatory
factors (Matouk, et. al. 2013).

Hypoxia and H19
One such approach to the H19 gene’s upregulation in cancerous cells is through hypoxia. Hypoxia is the loss of oxygen to areas of cancerous growth, and is considered a major
trigger for metastasis, tumor angiogenesis, and chemotherapy
resistance. Hypoxia is also considered to increase H19 expression in tumor cells. A study was done to investigate the
relation between hypoxia and H19 upregulation in tumor cells.
Carcinoma and Hepatocellular carcinoma cell lines were placed
in an Aneropack rectangular jar and supplemented with Gaspak
to create a hypoxic environment. Some cells where left with
normal oxygen conditions as a control. The cells were then
monitored by a hypoxic indicator. After twenty-four hours, the
cells were examined and RNA from each cell was extracted and
DPSOLÀHGWKURXJK3&59LHZHGRQWKHJHOWKHFHOOVXQGHUDQDHURELFFRQGLWLRQVH[SUHVVHGWKH+51$VLJQLÀFDQWO\PRUH
than the cells under normal oxygen conditions.
In a similar study, mice were injected with Hep3B, cells containing hepatitis B, which caused the proliferation of Hepatocellular
carcinoma on their dorsal side. A group of those mice were
then injected with siRNA, a H19 gene knockout. The results
showed that the mice that were treated with the siRNA showed
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DVLJQLÀFDQWUHWDUGDWLRQRIWXPRUJURZWKRI7KXVIURPWKLV
study it is clear that H19 plays a large role in tumor growth, and
is activated by hypoxia, which is common in cancerous growths
(Matouk, et. al. 2007, Matouk, et. al. 2005).

c-Myc and H19
Another factor that induces H19 transcription is the c-Myc
transcription factor. C-Myc is a transcription factor that, together with its obligate partner, protein Max, another transcription factor, binds to E-boxes, which are enhancer sequences on
the DNA that initiate transcription. C-Myc then promotes gene
transcription by initiating chromatin remodeling on the DNA
or RNA polymerase clearance. To assess the role of c-Myc in
tumor cells with increased H19 expression, a study was designed in which c-Myc was inserted into breast and glioblastoma
cell lines. Cells inserted with c-Myc showed a seven-fold to
ten-fold increase of H-19 expression based on Real-time PCR
readings. Breast and lung cancer cell lines were also used to
determine the correlation between elevated levels of c-Myc
and H19 and tumor growth. The cell lines containing elevated
levels of H19 and c-Myc were treated with siRNA to knock
down H19 expression. The cells with knockdown H19 exhibLWHG VLJQLÀFDQW UHWDUGDWLRQ RI WXPRULJHQHVLV7KXV F0\F ZDV
established as another factor that induces H19 upregulation and
thereby increases tumor growth (Barsyte, et. al. 2006).

contains bioluminescence. Results showed that serum-starved
cells had very little H19 expression, while cells in S phase had
remarkably increased levels of H19. The cells transfected with
the mutated promoter site had low H19 expression compared
to the wild type cells that had overall increased H19 expression,
especially at S phase (Fig. 1).
The correlation between H19 and E2F1 binding to its promoter is demonstrated when the comparison between the wild
type and mutated transfected cells are noted.The cells with wild
type H19 promoter sites showed a higher concentration of luciferase activities, since E2F1 was able to bind to the promoter
site and activate transcription, while the cells with the mutated
promoter sites exhibited a lower concentration of luciferase
activities since E2F1 was not able to bind to the mutated proPRWHUVLWH$GGLWLRQDOO\+·VDQG()·VGHÀQLWHUROHLQ*6
phase is observed by the fact that the greatest percentage of
cells were recorded during the S phase of the cell cycle.

E2F1 and H19
Another basis for increased H19 expression in cancer cells is
the E2F1 regulatory factor. E2F1 belongs to the E2F protein
family that regulates DNA by binding to promoters. E2F1 binds
to the H19 promoter and initiates its transcription. E2F regulation is based on the stages of the cell cycle. E2F1 is considered
a key factor in the transition from G1 to S in the cell cycle, as
it promotes the transcription of genes whose protein products
are necessary for the progression of the cell cycle and for imitating DNA duplication. Thus, increased E2F1 expression when
it is not the appropriate cell stage or time for cell replication
can lead to cancerous growths.
A study conducted assayed the correlation between increased
E2F1 and H19 gene expression in the S phase, as well as E2F1’s
impact on tumor growth. First, epithelial breast cells were
transfected with a luciferase reporter gene, a selectable marker
gene that, when expressed, causes the cells to emit a bioluminescence. Half of the cells were transfected with a luciferase reporter gene carrying the wild type H19 gene and the other half
with a mutated promoter site of an H19 gene, so E2F1 binding
is inhibited. The breast cells were then serum starved, and after
twenty-four hours, some cells were placed in a fresh medium to
stimulate their entry into cell cycle. After a set time, the cells
ZHUHWKHQFRPSDUHGXVLQJ)$&6DQDO\VLVDÁXRUHVFHQWVWUHQJWK
intensity test, because the luciferase reporter that was used
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)LJXUH$&HOOVZHUHWUHDWHGZLWKOXFLIHUDVHUHSRUWHUJHQHZLWK
HLWKHUZLOGW\SH :7 +SURPRWHUVLWHVRU+SURPRWHU
PXWDWHGLQWZR()VLWHV '0XW 7KHFHOOVZLWKWKHZLOGW\SH
SURPRWHUH[KLELWHGWKHKLJKHUFRQFHQWUDWLRQRIOXFLIHUDVHDFWLYLWLHV
than the mutated cells.
B. Shows the percentage of cells distributed throughout the cell
F\FOH1RWHWKHHOHYDWHG6SKDVHOLQH %HUWHDX[HWDO
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The second step of the study was to examine the roles of
H19 and E2F1 in cancer proliferation. Breast cancer cell lines
were obtained and the levels of E2F1 mRNa and H19 RNA were
calculated. Normal breast cells were used as a control.The data
showed that the expression of E2F1 and H19 were generally
corresponding. In the healthy breast cells there were low levels
of both E2F1 and H19 expression, while most of the cancer
cells showed notable activation of E2F1 and H19 gene. In one
line of cancer cells however, the E2F1 expression was high but
the H19 expression was comparatively low. This discrepancy
was attributed to heterogeneity of breast tumors. In general,
there is a correlation between E2F1 and H19 upregulated gene
expression in cancerous tissue (Berteaux, et. al. 2005).
Based on the studies discussed above, increased H19 expression is regulated by a number of regulatory factors, such as
c-Myc and E2F1. Their upregulation is also triggered by environmental stress conditions such as hypoxia and S phase induced
cells after serum starvation. However, cells under normal conGLWLRQVGRQRWGHPRQVWUDWHVLJQLÀFDQW+H[SUHVVLRQ $\HVK
HWDO 7KHVHÀQGLQJVUHLQIRUFHWKHHYLGHQFHWKDW+LV
upregulated in many cancer cells, for hypoxia and serum starvation are considered normal stages in tumor growth. Thus, the
tumor’s growth causes its further proliferation. As it outgrows
LWVEORRGVXSSO\VRPHSRUWLRQVRIWKHWXPRUODFNVXIÀFLHQWR[ygen and reside in hypoxic microenvironments, which in turn
triggers the increased expression of H19, further promoting
cancerous growth.
Some of the explanations of H19 gene upregulation in tumor
cells have been presented, and the therapeutic methods involving the H19 locus will now be discussed.

BC-819 Gene Therapy
In the past couple of years, BC-819, a plasmid involving a suicide
gene and the H19 promoter, has been developed and has successfully improved treatment of a number of cancers. BC-19 is
a double-stranded DNA vector that contains Diphtheria toxin
A sequence, which isused to destroy the cancer cell, and an H19
promoter sequence. It is mixed with Polyethylenimine transfectant (PEI), which allows for easier entry of the plasmid into the
rapidly dividing tumor cells. In some cases, PEI is not used and
BC-819 is injected intratumorally or by hepatic artery infusion
(Matouk, et. al. 2013).
Once BC-819 is in the cancer cell, the H19 promoter is activated and transcribed continuing with the Diphtheria toxin A
sequence, which causes cell death by disrupting protein synthesis. BC-819 can actively select tumor cells to destroy, since
only tumor cells have increased levels of H19 transcriptional
factors. BC-819 will enter healthy cells as well, but since they
lack the H19 regulatory factors, they will not transcribe the
plasmid and the cells will not be destroyed. BC-819 is an ingenious development that acts as a ‘search and destroy’ unit by

only killing cells that contain H19 transcriptional factors thereby
triggering their own demise (BioCanCell, 2017). BC-819 has
been semi-successful at treating bladder, pancreatic and ovarian
cancer patient (Fig. 2)s.

)LJXUH %LR&DQ&HOO

Bladder Cancer
In the United States, bladder cancer is the fourth most common cancer in men, with an estimated 74,000 annual incidents.
Around 70% of bladder cancer patients suffer recurrence within
ÀYH\HDUV$FKLHIJRDORIEDWWOLQJEODGGHUFDQFHULVLQSUHYHQWLQJ
its recurrence. For decades, the standard care option was the
BCG vaccine but the vaccine included drawbacks such as recurrence, resistance to the treatment, and negative side effects
(Matouk, et. al. 2013).
$SKDVHEVWXG\ZDVFRQGXFWHGWHVWLQJWKHHIÀFDF\RI%&
WUHDWPHQWRIEODGGHUFDQFHU3DWLHQWVZKRKDGFRQÀUPHG
recurrent bladder cancer and for whom BCG and chemotherapy had failed were recruited and BC-819 with PEI was administered to them. First, they were given six weekly treatments
RI %& DQG DW ZHHN QLQH VDIHW\ DQG HIÀFLHQF\ RI WUDQVIHU
were assessed. In cases of no toxicity or recurrence therapy
was discontinued in patients and follow up maintenance therapy
ZDVJLYHQIRUWKHGXUDWLRQRIWKH\HDU)URPWKHÀUVWFRKRUW
nine out of eighteen patients had complete resolution of the
target lesion within eight to ten weeks. Overall, 63% of paWLHQWV KDG UHFXUUHQFHIUHH WXPRUV IRU WKH ÀUVW WKUHH PRQWKV
after treatment and 48% had tumors for a year after treatment.
Additionally, the patients tolerated the treatment well with only
mild to moderate adverse effects.
Reports of Phase III trials have not yet been published but
trials are in progress as of the year 2016.

Pancreatic Cancer
The eighth leading cancer cause of death in the United States
LVSDQFUHDWLFFDQFHUZLWKDSRRUSURJQRVLVRIÀYH\HDUVXUYLYDO
The standard treatment for pancreatic cancer is gemcitabine,
a chemotherapy drug. However, gemcitabine has limited effect
because of its poor intracellular metabolism. Other methods
have been tried in combination with gemcitabine in the hope
of a more effective treatment, but none proved worthwhile.
Recently, BC-819 and gemcitabine were tested together on pancreatic patients in a phase 2b study that showed more promising
results. Patients received four week treatments of gemcitabine
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and were then administered with BC-819 through endoscopic
ultrasound. Continued treatment with gemcitabine and BC-819
was done for as long as the cancerous growth did not progress.
After three months, nine out of eleven patients showed encouraging results. Two had partial recovery and seven reached
a point of stable disease. There were several adverse events
mostly relating to liver function, but it was concluded that the
adverse events were not related to the BC-819 , but were rather due to the advanced stage of the cancer that all the patients
had (Matouk, et.a. 2013).

Ovarian Cancer
For women, ovarian cancer has a high mortality rate and is the
ÀIWKOHDGLQJFDXVHRIFDQFHUUHODWHGGHDWKLQWKH8QLWHG6WDWHV
Ovarian cancer patients generally have a poor prognosis, because
the initial detection of the cancer is usually after it has reached an
advanced stage. The typical course of treatment includes surgical
removal of the tumor followed by chemotherapy. Unfortunately,
most patients with the advanced stage tumor experience reODSVHDIWHUWUHDWPHQW,QWKHKRSHVRIÀQGLQJDEHWWHUDOWHUQDWLYH
WUHDWPHQWFRXUVHDSKDVHôVWXG\WHVWLQJWKHHIÀFDF\RI%&
plasmid was conducted on fourteen ovarian cancer patients. All
fourteen women had been pretreated with extensive chemotherapy. Different doses of BC-819 were administered to different
JURXSVRIWKHSDWLHQWV7KHÀUVWFRKRUWRISDWLHQWVZHUHWUHDWHG
for three weeks with BC-819, rested for a week, and were then
treated for six more consecutive weeks. This was followed by a
four week rest period. The second and third cohort were treated with increased dosages for three weeks, with four weeks of
rest and then an attempt at repeat treatment when possible. Of
the fourteen subjects, only 3 completed the study, while the rest
withdrew prematurely due to overall clinical deterioration. There
ZHUHÀIWHHQUHSRUWHGVHYHUHDGYHUVHHYHQWV\HWQRQHZHUHIURP
WKH GUXJ 7KHUH ZHUH KRZHYHU ÀYH DGYHUVH HYHQWV WKDW ZHUH
possibly related to BC-819 administration. The best outcome of
WKHWUHDWPHQWZDVDVWDEOHGLVHDVHZLWKLQVXIÀFLHQWVKULQNDJHRU
growth to qualify as either a partial response or progressive disease. The patients in the study all had advanced tumor growth,
EXW WKH ÀQGLQJV VXJJHVW WKDW ZLWK OHVV DGYDQFHG VWDJH RYDULDQ
cancer, BC-819 treatment would yield a partial response (Lavie,
et. al. 2017).
BC-819 shows great promise for cancer patients. Although
not every patient treated in the studies mentioned above had
a positive outcome from the treatment, no one’s medical state
was worsened. The study of the BC-819 treatment is still in
progress. The studies mentioned above are phase one or two
studies, which means they are being done to determine the
PD[LPXPWROHUDEOHGRVHRIWKHGUXJLWVVDIHW\DQGHIÀFLHQF\$
SKDVHWKUHHWULDOLVJHQHUDOO\WKHÀQDOWHVWSHUIRUPHGEHIRUHWKH
drug can be open to the public. A phase three trial is presently
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ongoing for bladder cancer, and a phase one/two has been completed for ovarian and pancreatic cancer.
Based on the various studies presented, gene therapy appears
to be a viable option for cancer treatment. Although in each
study there were some patients who did not fare well with this
form of treatment, as an overall option, gene therapy looks like
a promising alternative for cancer patients for whom standard
WUHDWPHQWLVLQVXIÀFLHQW

Gene Therapy and Leukemia
However, there have been studies that have shown that in its
attempt to rid the patient of his illness, gene therapy can actually
promote one of the deadliest cancers, leukemia.
In 2002, a group of infants with severe combined immunodeÀFLHQF\ 6&,' ZHUHWUHDWHGZLWKJHQHWKHUDS\EXWIRXURXWRI
WKHQLQHSDWLHQWVGHYHORSHGOHXNHPLDZLWKLQWKHQH[WÀYH\HDUV
This alarmed many patients and researchers, and was a major
setback in the advancement of gene therapy.
SCID is caused by a genetic mutation, making a patient with
it lack the IL-2 receptor ќ (IL2RG) gene. To restore the absent
gene, the infants in the study were treated with a therapeutic gene via a retroviral vector. However, the retroviral vector
works by inserting its genome near a transcription start site
in the host genome, allowing the virus’ long terminal repeats,
which are repeated identical sequences of DNA that enable
insertion into the host genome, to unintentionally turn on
transcription of other nearby sites. In these infants with SCID,
the LMO2 oncogene site was found near the insertion site and
was turned on, promoting leukemic growth (Hacein-Bay-Abina,
et.al. 2008).
The events of this gene therapy treatment were unfortunate,
and did remove some of the enthusiasm for gene therapy at the
time. However, the fact that this occurred on SCID patients and
not on cancer patients must be taken note of, thus gene therapy
might not be the right choice for SCID patient, but that does
not rule out cancer patients. Cancer patients may not have an
oncogene site near the insertion site for their therapeutic gene,
which completely removes the possibility of inducing leukemia.
In the research done, no reports have been made demonstrating that gene therapy for cancer patients further induced new
cancerous growths.

Conclusion
Although gene therapy as a treatment option for cancer has
had some setbacks and inconclusive results, it still provides
a large source of hope for cancer patients. The paradigm of
treating cancer is slowly shifting due to the ongoing progress
of gene therapy. Based on the studies presented above, overall
gene therapy, whether administered through a viral vector or
a non-viral vector, was successful in treating a portion of the
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patients. Additionally, even in the studies done in which small or
no substantial recovery was obtained, there were no considerable adverse effects on the patients treated with gene therapy.
This greatly contrasts standard treatments like chemotherapy
that cause an array of adverse effects on the patient without
necessarily providing complete removal of the cancer. Thus,
even though gene therapy may not provide a complete cure
against cancer, it is a promising alternative to standard cancer
treatment. With the constant hard work and progress of medical researchers and physicians that is presently taking place, it is
anticipative to say that gene therapy will provide great relief to
many cancer patients in the coming years.
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